`
`First Named Inventor: Rhett Mead SCHIFFMAN~—Confirmation No.: 4791
`
`Applicant: VISUS THERAPEUTICS, INC.
`
`Art Unit: 1629
`
`Application No.: 18/250,921
`
`Examiner: 7o Be Assigned
`
`371(c) Date: To Be Assigned
`
`Atty. Docket: 4902.0110003
`
`(U.S. National Phase ofInt’l Appl. No.
`PCT/US2021/057720;
`
`IA Date: November 2, 2021)
`
`Title: DEGRADANT COMPOUNDIN A MEDICAMENT
`
`Preliminary Amendment Under 37 C.ER.§ 1.115
`
`Commissionerfor Patents
`PO Box 1450
`Alexandria, VA 22313-1450
`
`Commissioner:
`
`Mail Stop Amendment
`
`In advanceof prosecution, Applicant submits the following amendments and remarks.
`
`Amendments to the Claims are reflected in the listing of claims which begins on page 2 of
`
`this paper.
`
`Remarks begin on page 10 ofthis paper.
`
`It is not believed that extensions of time are required beyond those that may otherwise be
`
`provided for in documents accompanying this paper. However, if additional extensions of time are
`
`necessary to prevent abandonment of this application, then such extensions of time are hereby
`
`petitioned under 37 C.F.R. § 1.136(a), and any additional fees required to continue prosecution or
`
`appeal of this application (including issue fee, fees for net addition of claims, or forwarding to appeal)
`
`are hereby authorized to be charged to our Deposit Account No. 19-0036.
`
`